FDA WARNING_LETTER - Germaphobix - January 01, 2026

The FDA issued a Warning Letter to Germaphobix on January 09, 2026, following a review of the company"s website (last visited January 2026) and prior communications. The letter addresses Germaphobix"s unauthorized marketing and distribution of a human immunodeficiency virus (HIV) serological diagnostic dried blood spot (DBS) card self-collection kit. The FDA determined that this kit is an unapproved medical device under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The primary violations include the kit being considered adulterated, as it lacks an approved premarket approval application or an investigational device exemption. It is also deemed misbranded because the required notification of intent to introduce the device into commercial distribution was not provided to the agency. Germaphobix had previously argued the kits were Lab-Developed Tests, but the FDA clarified that these self-collection kits require formal marketing authorization.

The FDA expressed concerns regarding the kit"s safety and effectiveness due to the absence of appropriate testing, data review, and authorization, noting potential issues with safe specimen collection, shipping integrity, and sample stability. Germaphobix is mandated to immediately cease all activities that result in the misbranding or adulteration of the HIV DBS card self-collection kit. The company must provide a written response to the FDA within fifteen working days, detailing the specific corrective actions taken to address these violations and prevent recurrence. Non-compliance may result in further regulatory actions.